DIMA Biotechnology LTD

Technology platform

Compared with the traditional monoclonal antibody preparation platform for hybridoma, we do not need to carry out hybridoma fusion. We can directly obtain positive B cells from peripheral blood of immunized animals after animal immunization and sequence the gene of monoclonal antibody. More than 1000 positive B cell clones can be obtained from a single immunized animal, and the overall positive clone rate is far higher than that of the traditional hybridoma platform. More+

For druggable targets, DIMA will construct ECD-Fc fusion protein and use HEK293 mammalian expression system for production. This will not only ensure the authentic posttranslational modifications from mammalian cells, but also have a high chance of obtaining proteins in good solubility and correct folding under standard buffer system. More+

about us

DIMA Biotechnology LTD is a research and development company of recombinant monoclonal antibody focusing on immune oncology products and services. DIMA’s proprietary B cell cloning and recombinant monoclonal antibody development platform, DimAb, can efficiently generate high-quality monoclonal antibodies in high throughput. The R&D team has many years of experience in monoclonal antibody development. We provide solutions for scientific research, clinical diagnosis and therapeutic R&D. More+